Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About PREDICTIVE TECHNOLOGY GROUP, INC.
Predictive Technology Group, Inc. engages in the development and commercialization of discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic and human cells, tissues, and human cellular and tissue-based products. The company is headquartered in Salt Lake City, Utah and currently employs 62 full-time employees. The company went IPO on 2007-07-11. The firm operates through two segments: Human Cell and Tissues Products (HCT/Ps) and diagnostics and therapeutics. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The firm's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. The company offers genetic tests through a number of Advanced Reproductive Technologies (ART) clinics.The Company’s tests include ARTguide and FertilityDX. The RTguide test is a genetic test for women experiencing infertility and other genetic condition.
Industry: Pharmaceutical Preparations Peers: GENEREX BIOTECHNOLOGY CORP Rebus Holdings, Inc.
